STOCK TITAN
  1. Home
  2. Sec-filings
  3. IMNM
  4. [Form 4] Immunome Inc. Insider Trading Activity

Immunome (IMNM) director’s entity sells 36,088 shares under 10b5-1 plan

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Immunome Inc. director Isaac Barchas reported indirect sales of Immunome common stock executed by AMBHMC II LLC ("ABHMC"), an entity he helps manage. On August 6 and 7, 2026, ABHMC sold a total of 36,088 shares of common stock in open market or private transactions at a weighted average price of $26.06 per share, with price ranges between $26.00 and $26.3318 depending on the trade. These sales occurred automatically under a Rule 10b5-1 trading plan adopted by ABHMC on March 31, 2026. Barchas reports that ABHMC owns the shares and disclaims beneficial ownership except to the extent of any pecuniary interest. A separate line reports 103,259 shares of Immunome common stock held directly by Barchas as of August 6, 2026.

Positive

  • None.

Negative

  • None.

Insights

Analyzing...

Insider Barchas Isaac
Role Director
Sold 36,088 shs ($940K)
Type Security Shares Price Value
Sale Common Stock F1, F4, F3 15,248 $26.06 $397K
Sale Common Stock F1, F2, F3 20,840 $26.06 $543K
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 72,416 shares (Indirect, See footnote); Common Stock — 103,259 shares (Direct)
Footnotes (4)
  1. F1. The reported sale of these shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by AMBHMC II LLC ("ABHMC") on March 31, 2026.
  2. F2. The weighted average sale price for the transaction report was $26.06, and the range of prices were between $26.00 and $26.3318, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
  3. F3. ABHMC owns the shares of Issuer common stock. The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares.
  4. F4. The weighted average sale price for the transaction report was $26.06, and the range of prices were between $26.00 and $26.25, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
Shares sold August 6, 2026 20,840 shares Indirect sale by ABHMC II LLC at weighted average price $26.06
Shares sold August 7, 2026 15,248 shares Indirect sale by ABHMC II LLC at weighted average price $26.06
Total shares sold 36,088 shares Combined indirect sales reported for August 6–7, 2026
Weighted average sale price $26.06 per share Applies to both reported sale dates with stated price ranges
Price range Aug 6, 2026 $26.00–$26.25 Range of prices for August 6, 2026 sale transactions
Price range Aug 7, 2026 $26.00–$26.3318 Range of prices for August 7, 2026 sale transactions
Direct holdings reported 103,259 shares Common stock held directly by Isaac Barchas as of August 6, 2026
10b5-1 plan adoption date March 31, 2026 Date ABHMC II LLC adopted the Rule 10b5-1 trading plan
Rule 10b5-1 trading plan regulatory
"The reported sale of these shares occurred automatically pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average sale price financial
"The weighted average sale price for the transaction report was $26.06"
pecuniary interest financial
"disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest"
indirect ownership financial
"ABHMC owns the shares of Issuer common stock…the Reporting Person is a managing member"
beneficial ownership regulatory
"This report shall not be deemed an admission that Reporting Person is the beneficial owner"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →

FAQ

What insider transactions did Immunome (IMNM) report for Isaac Barchas?
Immunome reported that an entity associated with director Isaac Barchas, ABHMC II LLC, sold 36,088 shares of common stock on August 6–7, 2026 under a Rule 10b5-1 trading plan, at a weighted average price of $26.06 per share.

At what prices were the Immunome (IMNM) shares sold in the August 2026 insider trades?
The reported sales had a weighted average price of $26.06 per share. On August 6, 2026, prices ranged from $26.00 to $26.25, and on August 7, 2026, from $26.00 to $26.3318, inclusive.

How many Immunome (IMNM) shares did ABHMC II LLC sell on each date?
ABHMC II LLC sold 20,840 shares of Immunome common stock on August 6, 2026 and 15,248 shares on August 7, 2026, for a combined total of 36,088 shares reported as indirect sales.

Were the August 2026 Immunome (IMNM) insider sales made under a 10b5-1 plan?
Yes. The filing states the sales occurred automatically under a Rule 10b5-1 trading plan adopted by AMBHMC II LLC on March 31, 2026, indicating the transactions were pre-arranged.

Does Isaac Barchas claim full beneficial ownership of the Immunome (IMNM) shares sold?
No. The filing explains that AMBHMC II LLC owns the shares, and Barchas, as a managing member and power of attorney holder, disclaims beneficial ownership except to the extent of any pecuniary interest in those shares.

What direct Immunome (IMNM) holdings does Isaac Barchas report after these transactions?
A separate entry reports that Isaac Barchas directly held 103,259 shares of Immunome common stock as of August 6, 2026. This figure relates to his direct ownership and is reported apart from the indirect ABHMC II LLC holdings.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Barchas Isaac
(Last)(First)(Middle)
C/O IMMUNOME, INC.
18702 N. CREEK PARKWAY, SUITE 100
(Street)
BOTHELL WASHINGTON 98011
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Immunome Inc. [ IMNM ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/06/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/06/2026S(1)20,840D$26.06(2)87,664ISee footnote(3)
Common Stock08/07/2026S(1)15,248D$26.06(4)72,416ISee footnote(3)
Common Stock103,259D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The reported sale of these shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by AMBHMC II LLC ("ABHMC") on March 31, 2026.
2. The weighted average sale price for the transaction report was $26.06, and the range of prices were between $26.00 and $26.3318, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
3. ABHMC owns the shares of Issuer common stock. The Reporting Person is a managing member and holder of a power of attorney with the ability to exercise voting and investment power over the shares of Issuer common stock held by ABHMC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares.
4. The weighted average sale price for the transaction report was $26.06, and the range of prices were between $26.00 and $26.25, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
/s/ Sandra Stoneman, Attorney-in-Fact08/10/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR